Trial intelligence / Profile preview

Phase 2 open-label lorlatinib in relapsed ALK-positive lymphoma after ALK inhibitors

2016-003970-41Phase 2Active

Sponsor

University of Milano-Bicocca

Start

Jun 2021

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1